Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN 21 1 5 30 versus NORDETTE 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN 21 1 5 30 versus NORDETTE 28.
LOESTRIN 21 1.5/30 vs NORDETTE-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial morphology.
Combined estrogen-progestin oral contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily for 21 consecutive days, followed by 7 days off therapy.
One tablet orally once daily for 28 consecutive days.
None Documented
None Documented
Ethinyl estradiol: ~12-14 h; Norethindrone: ~5-12 h. Steady-state achieved in ~5-10 days.
Ethinyl estradiol: 13-27 hours (mean 17 hours); Levonorgestrel: 11-45 hours (mean 24 hours); clinical context: steady-state reached after 5-7 days.
Primarily hepatic metabolism; ~40-60% renal, 20-30% biliary/fecal.
Renal: ~50% as metabolites, ~20% unchanged; Fecal: ~30% as metabolites; Biliary: minimal.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive